ILUMETRI

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug ILUMETRI contains one active pharmaceutical ingredient (API):

1	Tildrakizumab UNII DEW6X41BEK - TILDRAKIZUMAB
	Tildrakizumab is a humanized IgG1/k monoclonal antibody that specifically binds to the p19 protein subunit of the interleukin-23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
	Read more about Tildrakizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ILUMETRI Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC17		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1780130, 1780488
ES	Centro de información online de medicamentos de la AEMPS	1181323001
FR	Base de données publique des médicaments	69596271
GB	Medicines & Healthcare Products Regulatory Agency	364267, 367558
LT	Valstybinė vaistų kontrolės tarnyba	1086234, 1086387
NL	Z-Index G-Standaard, PRK	198293
PL	Rejestru Produktów Leczniczych	100411378
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66238001, W66238002